Activated ERK level was significantly higher in post-treatment biopsy compared with baseline regardless of EGFR TKI regimen (Fig. 1b and c), suggesting that increased ERK activation may be associated with acquired resistance to EGFR TKI in EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.